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Introduction
According to the 2015 World Alzheimer Report, 46.8 million 
people worldwide are living with dementia in 2015. This 
number will almost double every 20 years. Much of the 
increase will take place in low and middle income countries 
(lMıcs): in 2015, 58% of all people with dementia live in 
lMıcs, rising to 63% in 2030 and 68% in 2050. The Report 
updates data on the prevalence, incidence, cost and trends 
of dementia worldwide. ıt also estimates how these numbers 
will increase in the future, leaving us with no doubt that 
dementia, including Alzheimer’s disease and other causes, 
is one of the biggest global public health and social care 
challenges facing people today and in the future (1).
cholinesterase (che) inhibitors constitute the only 
therapeutic class of agents approved for the symptomatic 
treatment of Alzheimer’s disease (AD). These drugs enhance 
cholinergic function by inhibiting enzymes that degrade 
acetylcholine (Ach), thereby increasing the availability 
of Ach to stimulate nicotinic and muscarinic receptors 
within the brain. Four che inhibitors are currently licensed 
for the symptomatic treatment of AD: tacrine, donepezil, 
rivastigmine and galantamine. Although all of these agents 
increase levels of Ach in the brain, they differ substantially in 
pharmacological and pharmacokinetic profiles; for instance: 
enzymes inhibited, potency, brain selectivity, chemical class, 
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ın the present study, a series of 4(3H)-quinazolinone derivatives 
(5a-f) were synthesized through the cylization reaction of 
substituted 1,3,4-thiadiazoles containing an aromatic primary 
amin and anthranilic acid in the presence of acetic anhydride 
and acetic acid. The structures of the synthesized compounds 
were confirmed by elemental analysis, ıR, 1h-nMR and 
mass spectroscopic (5b and 5f) methods. each derivative was 
evaluated for its ability to inhibit acetylcholinesterase (Ache) 
using a modification of ellman’s spectrophotometric method. 
compounds 2-methyl-3-{4-[5-(ethylamino)-1,3,4-thiadiazol-
2-yl]phenyl}quinazolin-4(3H)-one (5b) and 2-methyl-3-{4-[5-
(cyclohexylamino)-1,3,4-thiadiazol-2-yl]phenyl}quinazolin-
4(3H)-one (5d) can be identified as promising anticholinesterase 
agents due to their inhibitory effect when compared with 
donepezil as a reference drug. 
Keywords: 4(3H)-Quinazolinone, 1,3,4-thiadiazole, anti-
acetylcholinesterase activity.
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mechanism of action, metabolism and dose-dependent effects. 
Theoretically, such differences should differentiate the che 
inhibitors with respect to clinical efficacy and safety (2). 
Scientists have widely studied on 1,3,4-thiadiazole derivatives 
as potential drugs to treat AD (3, 4). Additionally, 4(3H)-
quinazoline compounds, which have diverse pharmacological 
activities (5-9) as well as important pharmacophore groups, 
exhibit cholinesterase inhibitory activity (10-12). eventually, 
in this present study, the synthesis of  compounds bearing 
both 4(3H)-quinazolinone and 1,3,4-thiadiazole moieties 
was achieved and the synthesized compounds wer evaluated 
for their ability to inhibit acetylcholinesterase (Ache) using 
a modification of ellman’s spectrophotometric method.  
Chemistry
Various synthesis methods are reported about the cyclization 
of quinazolinone derivatives (13-16). ln this research, 
2-methyl-3-substituted-4(3H)-quinazolinones were synthe-
sized by cyclization of anthranilic acid and arylamines 
with acetic anhydride. The synthetic route of substituted 
4(3H)-quinazolinones is represented in Scheme 1. The 
arylamines 4a-f were prepared from ethyl 4-aminobenzoate 
by us (17). ın a second step, the mixture of anthranilic acid 
and acetic anhydride were refluxed for 4 hours to form the 
intermediate 2-methylbenzoxazinone.  The reaction medium 
was evaporated and then refluxed for 4 hours with 4a-f in 
glacial acetic acid to obtain 5a-f (18).  We gained the  4(3H)-
quinazolinones (5a-f) in a single-step and satisfied yield 
(66 -75 %).
Scheme 1. Synthesis of   2-methyl-3-{4-[5-(substitutedamino)-
1,3,4-thiadiazol-2-yl]phenyl}quinazolin-4(3H)-one (5a-f)
 The compound 5e was synthesized by Khalil and habib with 
a different method (19). The synthetic route of 2-methyl-3-{4-
[5-(phenylamino)-1,3,4-thiadiazol-2-yl]phenyl}quinazolin-
4(3H)-one is represented in Scheme 2.  
Scheme 2. Synthesis of 2-methyl-3-{4-[5-(phenylamino)-
1,3,4-thiadiazol-2-yl]phenyl}quinazolin-4(3H)-one 
Pharmacology
AChE Inhibition
All compounds were subjected to a slightly modified method 
of ellman’s test (23) in order to evaluate their potency to 
inhibit the Ache.  The spectrophotometric method is based 
on the reaction of released thiocholine to give a coloured 
product with a chromogenic reagent 5,5-dithio-bis(2-
nitrobenzoic)acid (DTnB). Ache, (e.c.3.1.1.7 from electric 
eel, 500 units), and donepezil hydrochloride were purchased 
from Sigma–Aldrich (Steinheim, Germany). potassium 
dihydrogen phosphate, DTnB, potassium hydroxide, sodium 
hydrogen carbonate, gelatine, acetylthiocholine iodide 
(ATc) were obtained from Fluka (Buchs, Switzerland). 
Spectrophotometric measurements were performed on 
a 1700 Shimadzu UV-1700 UV–Vis spectrophotometer. 
cholinesterase activity of the compounds was measured 
in 100 mM phosphate buffer (ph 8.0) at 25 °c, using ATc 
as substrates, respectively. DTnB (10 mM) was used in 
order to observe absorbance changes at 412 nm. Donepezil 
hydrochloride was used as a positive control (table 1) (24).
Enzymatic assay
enzyme solutions were prepared in gelatin solution (1 %), at a 
concentration  of  2.5 units/ml. Ache and compound solution 
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(50 µl) which is prepared in 2 % DMSo at a concentration 
range of 10-1-10-6 mM were added to 3.0 ml phosphate buffer 
(ph 8±0.1) and incubated at 25 °c for 5 min. The reaction 
was started by adding  DTnB (50 µl) and ATc (10 µl) to 
the enzyme-inhibitor mixture. The production of the yellow 
anion was recorded for 10 min at 412 nm. As a control, an 
identical solution of the enzyme without the inhibitor is 
processed following the same protocol. The blank reading 
contained 3.0 ml buffer, 50 μl 2 % DMSo, 50 μl DTnB and 
10 μl substrate. All processes were assayed in triplicate. The 
inhibition rate (%) was calculated by the following equation:
ınhibition % = (Ac–Aı) / Ac x 100
Where Aı is the absorbance in the presence of the inhibitor, 
Ac is the absorbance of the control and AB is the absorbance 
of blank reading. Both of the values are corrected with blank-
reading value. SpSS for Windows 15.0 was used for statistical 
analysis. Data were expressed as Mean ± SD.
table 1.  % Ache inhibition of the compounds and ıc50 
values 
   comp.
Ache ınhibition (%)
1 mM      0.1 mM           IC50 (mM)
5a 11.62 ± 1.78 2.29 ± 2.32 > 1
5b 27.10 ± 2.51 14.21 ± 
1.63
> 1
5c 8.22 ± 3.02 0.11 ± 2.01 > 1
5d 25.84 ± 0.59 11.43 ± 
2.13
> 1
5e 7.7 ± 3.09 2.1 ± 2.33 > 1
5f 8.04 ± 2,97 2.01 ± 1.55 > 1
Donepezil 99.01 ± 4.89 95.52 ± 
5.01
0.054 ± 0.002 
(µM)
Results and Discussion 
A series of 4(3H)-quinazolinone derivatives (5a-f) were 
synthesized through the cylization reaction of substituted 
1,3,4-thiadiazoles containing an aromatic primary amin 
and anthranilic acid in the presence of acetic anhydride and 
acetic acid. The structures of the synthesized compounds 
were confirmed by elemental analysis  ıR, 1h-nMR and mass 
spectroscopic (5b and 5f) methods. 
The ıR spectra of substituted 4(3H)-quinazolinones were 
evaluated and the common bands of the main structure 
were observed in expected areas, correlating with the 
literature. The ıR spectra of 4(3H)-quinazoline derivatives 
5a-f was shown strectching bands at 3343-3167 cm-1 and 
3171-3003 cm-1 which have assigned to secondary amine 
n-h and aromatic =c-h, respectively. The asymmetric and 
symmetric strectching bands of c-h were observed at 2999-
2849 cm-1. ın addition, the absorption bands at 1682-1668 
cm-1   (quinazoline ring c=o), 1444-1609 cm-1 (aromatic 
c=c  strectching band  and n-h bending band), 816-835 
cm-1 (characterized phenyl ring substitution bands) and 
698-683 cm-1 (thiadiazole ring c-S-c stretching bands) were 
detected (20-22).
The 1h-nMR spectra of the 2-methyl-3-[4-(5-
substitutedamino-1,3,4-thiadiazole-2-yl)phenyl]-4(3H)-
quinazolinones (5a-f) in DMSo-d6 were evaluated and 
the chemical shifts of aliphatic and aromatic protons and 
n-h protone of seconder amine were observed correlating 
with the published data. ın the 1h-nMR spectra of these 
compounds, the signals representating the quinazoline ring 
methyl proton at second site appeared at 2.08-2.18 ppm as 
a singlet whereas methyl protons of 5c compound appeared 
at 2.13-2.17 ppm as a double singlet. Also, secondary amine 
n-h resonances of these compounds  and aromatic protons 
were observed in expected region (19).
eı-MS spectra of compounds 5b and 5f showed molecular 
ion (M+) peaks which confirmed their molecular weights. 
The proposed mass fragmentation pathway of compound 5b 
was given in Scheme 3.
Scheme 3. proposed mass fragmentation pathway of 
compound 5b
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The anticholinesterase effects of synthesized compounds 
(5a-f) were determined by modified ellman’s 
spectrophotometric method (table 1). Among these 
compounds 5b with ethylamino substitution and 5d with 
cyclohexylamino were found as the most active compounds. 
The inhibition percentages were calculated 27.10 and 14.21 
% at 1 and 0.1 mM concentrations for compound 5b and the 
inhibition percentages were calculated 25.84 and 11.43 % at 1 
and 0.1 mM concentrations for compound 5d. The ıc50 values 
could not be defined none of all compounds. compound 5a 
showed moderate activity with the inhibition percentages 
11.62 and 2.29 % at 1 and 0.1 mM concentrations. The other 
compounds 5c, 5e and 5f showed relatively weak activity and 
the inhibiton values were found less than 8.22 %. Standard 
drug Donepezil was studied at lower concentrations for the 
purpose of finding ıc50 value and it was determined as 0.054 
µM. none of the compounds showed comparable activity 
with donepezil and significant anticholinesterase activity 
contrary to expectations.
Experimental 
All chemicals are commercially available and used as received. 
Melting points were determined on Schmelzpunktbestimmer 
SMp ıı and are uncorrected. elemental analysis apparatus 
was Kleinfeld SMp-ıı. The ıR spectra were recorded on 
Schimadzu FTıR 8400 S spectrometer. 1h-nMR spectra 
were recorded on Bruker AVAnce-DpX 400 using TMS as 
an internal standard. The mass spectra were measured on 
Agilant 1100 lc-MS. 
Synthesis of 2-methyl-3-{4-[5-(substitutedamino)-1,3,4-
thiadiazol-2-yl]phenyl}quinazolin-4(3H)-ones [5a-f]
Anthranilic acid  (0.002 mol, 0.274 g) and 0.6 ml acetic 
anhydride were refluxed under anhydrous condition for 4 h. 
excess of acetic anhydride was distilled off under reduced 
pressure. To the mixture obtained, 4a-f (0.01 mol) in glacial 
acetic acid was added and refluxed for 4 h, and the obtained 
reaction mixture was poured into crushed ice and kept 
overnight. The solid was filtered, washed with water, dried 
and recrystallized from ethanol (18).          
2-Methyl-3-{4-[5-(substitutedamino)-1,3,4-thiadiazol-2-
yl]phenyl}quinazolin-4(3H)-one [5a-f]
2-Methyl-3-{4-[5-(methylamino)-1,3,4-thiadiazol-2-yl]
phenyl}quinazolin-4(3H)-one [5a]       
M.p. 274-275 ºc; yield 67 %; brown crystals; ıR (υmax,  cm-1): 
3343 (n-h ); 2920 (c-h); 1674 (c=o); 1h-nMR (400 Mhz, 
DMSo-d6, d): 2.17 (s, 3h, -ch3), 2.95 (d, 3h, J: 4.80 hz, -nh-
ch3), 7.53 (t, 1h, quinazoline c6-h), 7.57 (d, 2h, J: 8.00 hz 
protons in meta position  of thiadiazole), 7.68 (d, 1h, J: 8.40 
hz, quinazoline c8-h), 7.86 (t, 1h, quinazoline c7-h), 7.94 
(d, 2h, J: 8.52 hz, protons in ortho position  of thiadiazole), 
7.98  (d, 1h, J: 4.80 hz, -nh), 8.11 (dd, 1h, J: 7.80, J: 1.00 
hz, quinazoline c5-h); Anal. calc. for c18h15n5oS (349.41): 
c, 61.87; h, 4.33; n, 20.04; S, 9.18 %. Found: c, 61.49; h, 
4.05; n, 19.94; S, 8.79 %. 
2-Methyl-3-{4-[5-(ethylamino)-1,3,4-thiadiazol-2-yl]
phenyl}quinazolin-4(3H)-one [5b]       
M.p. 255-256 ºc; yield 69 %; white powder; ıR (υmax,  cm-1): 
3308 (n-h.), 2982 (c-h), 1672 (c=o); 1h-nMR (400 Mhz, 
DMSo-d6, d): 1.22 (t, 3h, –ch2-ch3), 2.18 (s, 3h, -ch3), 
3.32-3.38 (-nh–ch2 was over shadow by DMSo peak), 
7.51-7.58 (m, 3h, quinazoline c6-h and protons in meta 
position  of thiadiazole), 7.68 (d, 1h, J: 7.79 hz, quinazoline 
c8-h), 7.85 (t, 1h, quinazoline c7-h), 7.94 (d, 2h, J: 8.52 hz, 
protons in ortho position  of thiadiazole), 8.03 (1h, t, -nh), 
8.11 (dd, 1h, J: 7.98 hz, J: 1.25 hz, quinazoline c5-h). Anal. 
calc. for c19h17n5oS (363.44): c, 62.79; h, 4.71; n, 19.27; S, 
8.82 %.  Found: c, 62.36; h, 4.65; n, 19.11; S, 8.64 %. (+) eS-
MS (70 eV): m/z (%): 364 (81) (M+1)+.
2-Methyl-3-{4-[5-(propylamino)-1,3,4-thiadiazol-2-yl]
phenyl}quinazolin-4(3H)-one [5c]       
M.p. 240-242 ºc;  yield 72 %; cream crystals; ıR (υmax,  cm-1): 
3167 (n-h), 2965, 2934 (c-h), 1682 (c=o). 1h-nMR (400 
Mhz, DMSo-d6, d): 0.95 (t, 3h, -ch2-ch2-ch3), 1.60-1.68 
(m, 2h, -ch2-ch2-ch3), 2.13, 2.17 (2s, 3h, -ch3), 3.21-3.42 
(-ch2-ch2-ch3 was over shadow by DMSo peak), 7.14-
11.09 (m, 9h, Ar-h ve -nh). Anal. calc. for c20h19n5oS 
(377.46): c, 63.64; h, 5.07; n, 18.55;  S, 8.49 %.  Found: c, 
62.21; h, 5.97; n, 18.71; S, 8.15 %. 
2-Methyl-3-{4-[5-(cyclohexylamino)-1,3,4-thiadiazol-2-
yl]phenyl}quinazolin-4(3H)-one [5d]       
M.p. 244-245 ºc; yield 66 %; cream powder; ıR (υmax, cm-1): 
3306 (n-h), 2915, 2849 (c-h), 1668 (c=o). 1h-nMR (400 
Mhz, DMSo-d6, d): 1.00-2.20 (m, 10h, cyclohexyl -ch2-
), 2.18 (s, 3h, -ch3), 3.52-3.70 (bs, 1h, cyclohexyl -ch-), 
7.51-7.57 (m, 3h, quinazoline c6-h and protons in meta 
position  of thiadiazole), 7.68 (d, 1h, J: 8.33 hz, quinazoline 
c8-h), 7.86 (t, 1h, quinazoline c7-h), 7.93 (d, 2h, J: 7.92 hz, 
protons in ortho position  of thiadiazole), 8.00  (d, 1h, J: 7.34 
hz, -nh), 8.12 (dd, 1h, J: 7.98 hz, J: 1.23 hz, quinazoline c5-
h). Anal. calc. for c23h23n5oS (417.53); c, 66.16; h, 5.55; n, 
16.77; S, 7.68 %. Found: c, 65.83; h, 5.39; n: 16.25; S, 7.38 % . 
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2-Methyl-3-{4-[5-(phenylamino)-1,3,4-thiadiazol-2-yl]
phenyl}quinazolin-4(3H)-one [5e] (19) 
M.p.  272-275 ºc; yield 70 %; white powder; ıR (υmax,  cm-
1): 3279 (n-h), 2999, 2969 (c-h), 1672 (c=o); 1h-nMR 
(400 Mhz, DMSo-d6, d): 2.08 (s, 3h, -ch3), 7.34-7.88 (m, 
13h, Ar-h), 10.21 (s, 1h, -nh). Anal. calc. for c23h17n5oS 
(411.48): c, 67.13; h, 4.16; n, 17.02; S, 7.79 %. Found: c, 
66.80; h, 4.06;  n, 17.43; S, 8.15 %. 
2-Methyl-3-(4-{5-[(4-nitrophenyl)amino)-1,3,4-
thiadiazol-2-yl}phenyl)quinazolin-4(3H)- one [5f]       
M.p.ñ 350 ºc; yield 75 %, green powder; ıR (υmax, cm-1): 3273 
(n-h), 2932 (c-h), 1670 (c=o).  1h-nMR (400 Mhz, 
DMSo-d6, d): 2.16 (s, 3h, -ch3), 7.51-8.28 (m, 12h, Ar-h), 
11.35 (s, 1h, -nh). Anal. calc. for c23h16n6o3S (456.47): c, 
60.52; h, 3.53; n, 18.41; S, 7.02 %. Found: c, 59.18; h, 3.76; 
n, 17.89; S, 7.13 %. (+) eS-MS (70 eV): m/z (%) =  457 (100) 
(M+1)+.
Conclusion
We have successfully developed a single-step and efficient 
synthesis of new 4(3H)-quinazolinone derivatives using 
anthranilic acid and substituted 1,3,4-thiadiazoles bearing 
an aromatic primary amin under acidic conditions. The 
structures of the synthesized compounds were confirmed 
by elemental analysis, ıR, 1h-nMR and mass spectroscopic 
(5b and 5f)  methods. compounds 5b and 5d can be identified 
as promising anticholinesterase agents due to their inhibitory 
effect when compared with donepezil  as a reference drug. 
1,3,4-tiyadiazol içeren bazı 4(3H)-kinazolinon türevlerinin 
sentezi  ve anti-asetilkolinesteraz aktiviteleri
Öz
Bu çalışmada, aromatik pirimer amin içeren sübstitüe 
1,3,4-tiyadiazoller ile antranilik asitin asetik asit ve asetik 
anhidritli ortamdaki siklizasyonundan bir seri 4(3H)-
kinazolinon türevi (5a-f) sentez edildi. Bileşiklerin yapıları 
ıR, 1h-nMR, kütle spektroskopisi (5b ve 5f) ve elementel 
analiz yöntemleri kullanılarak aydınlatıldı. Bileşiklerin aktivite 
tayini ellman’ın modifiye edilmiş spektrofotometrik yöntemi 
kullanılarak yapıldı. Donepezil standardı ile karşılaştırıldığında 
bileşik 5b (2-metil-3-{4-[5-(etilamino)-1,3,4-tiyadiazol-2-il]
fenil}kinazolin-4(3H)-on) ve bileşik 5d (2-metil-3-{4-[5-
(siklohegzilamino)-1,3,4-tiyadiazol-2-il]fenil}kinazolin-4(3H)-
on) inhibitör etkilerine göre antikolinesteraz ajanları olarak 
tanımlanabilirler. 
Anahtar kelimeler: 4(3H)-Kinazolinon, 1,3,4-tiyadiazol, anti-
asetilkolinesteraz aktivite
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